GlassScriptPhysician profile
Scott N Hoffman
NPI 1740713593
$2,080.09
in general payments reported to CMS, 2019-2025
25 companies · $904 in 2025
The $904 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.90 · 2021: $97.68 · 2022: $219 · 2023: $603 · 2024: $233 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.13 | 2023-2025 | |
| Lilly USA, LLC | $162.64 | 2022-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $142.00 | 2020-2025 | Ozempic, Rybelsus |
| Stryker Corporation | $124.33 | 2025 | Easyfuse |
| Pfizer INC. | $121.21 | 2023-2025 | |
| Exact Sciences Corporation | $102.49 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $97.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $82.54 | 2025 | Austedo Xr |
| Abbott Laboratories | $77.44 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $75.13 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $65.74 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $65.18 | 2021-2023 | Breztri, Farxiga |
| Xeris Pharmaceuticals, INC. | $56.50 | 2024-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $52.43 | 2025 | Nexletol |
| Radius Health, INC. | $48.18 | 2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.53 | 2024-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $39.68 | 2021 | |
| Almatica Pharma LLC | $39.03 | 2021-2022 | |
| Axsome Therapeutics, INC. | $33.60 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $30.65 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Phathom Pharmaceuticals, INC. | $30.29 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $25.51 | 2023 | Jynarque |
| E.R. Squibb & Sons, L.L.C. | $22.08 | 2022 | |
| Dexcom, INC. | $20.02 | 2023 | Dexcom G6 Transmitter |
| Amgen INC. | $16.28 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.